Fillerina, page-4

I cut and paste the article to highlight the points (imo) worth noting..

1. Cosmetic and Plastic Surgery economy is worth $1.5B
2. Premium Skin Care market worth $ 1/2 B per year
3. the trend is towards Natural (organic) products ie Evolis and Fillerina
4. Cellmid are not a one trick pony ( watch that space)

my opinion
1. Fillerina occupies a unique space in the market that hasn't been fully exploited and appeals to customers who don't want to be injected. ( is 75% of the total market)
2.   This market segment could be greater than the those who use botox. ie easily >$100M per annum
3. In Australia and NZ this will easily outperform Evolis.
4. Management are doing an excellent job positioning the company for growth (it costs money to do this)
These companies want to help erase wrinkles without needles

Australian customers want to fight wrinkles, but the businesses smoothing the way to success with anti-ageing cosmetics say that few want to go under the knife.
According to IBISWorld, the country’s cosmetic and plastic surgery procedure space is worth $1.5 billion a year, but close to one quarter of procedures in this space are “non-surgical”, including skin treatments that don’t involve things like injections.

Maria Halasz, CEO of Cellmid.
Photo: Wolter Peeters.
Entrepreneurs that play in the ‘wellness cosmetics’ space say they’re jumping on an upswing of customers who want the results of anti-ageing treatments but want a more natural or less intense option.
The nation's premium skincare product market is also approaching the half a billion dollar mark, worth $435 million this year and growing by 13 per cent a year, according to IBISWorld, powered by demand for organic beauty products.
'People don't like to be injected'

In the midst of this, a range of companies are adding anti-ageing products to their project suites. Biotechnology company Cellmid is working on therapies for chronic kidney disease in one part of its business, but selling anti-ageing and hair loss prevention products in the other.


You can now have major cosmetic procedures in your lunch hour
Chief executive Maria Halasz says the company, which turned over more than $5 million last year, decided to secure licensing for the anti-ageing product Fillerina because it was clear customers wanted anti-wrinkle treatments but only a small slice of the Australian market was going straight to injectable treatments.
“It’s about two things: people don’t like to be injected, and then there’s the artificial nature of the injection results,” she says.
Customers are really only focused on two things in the anti-ageing market: wrinkle prevention and wrinkle erasure, Halasz says.

Cellmid’s Fillerina products are topical treatments containing various sizes of hyaluronic acid molecules, designed to smooth out skin from the outside rather than having a substance injected.




Halasz says the product, developed in Switzerland, has undergone 30-day safety tests and has a good risk profile.
The products complement Cellmid's hair loss prevention product range, Evolis.
She says customers are increasingly going into pharmacies to buy their cosmetics and that Cellmid is well placed to provide an anti-ageing alternative in that space.

While not a complete alternative to the likes of Botox, the anti-ageing products do “complement” them and capture consumers who would never get more invasive treatments in the first place, she says.
'They want a more natural approach'